. 2012 Sep 24;209(10):1883–1899. doi: 10.1084/jem.20120502

Table 2.

Depletion of NK cells and macrophages by anti-CD122 Ab or CLO treatment

Treatment	NK		MAC
	BM	SP	BM	SP
	%	%	%	%
NS mice
PBS	2.7 ± 0.1 (3)	19.7 ± 1.6 (3)	11.0 ± 2.9 (3)	46.3 ± 1.0 (3)
CD122	0.9 ± 0.1 (3)^c	10.3 ± 1.0 (3)^c	11.0 ± 1.4 (3)	54.5 ± 1.4 (3)^c
CLO	3.0 ± 0.2 (5)	34.0 ± 2.1 (5)^c	1.7 ± 0.2 (4)^b	2.1 ± 0.2 (4)^c
*NS-Idd13* mice**
PBS	2.7 ± 0.7 (3)	22.9 ± 1.3 (3)	4.8 ± 1.2 (3)	37.3 ± 1.5 (3)
CD122	0.8 ± 0.2 (3)^a	7.8 ± 1.1 (3)^c	6.6 ± 1.5 (3)	48.1 ± 1.4 (3)^c
CLO	3.0 ± 0.4 (5)	25.7 ± 3.2 (5)	1.6 ± 0.2 (5)^a	2.6 ± 0.3 (5)^c

Percentage of NK cells (F4/80⁻CD49b⁺) and macrophages (MAC; F4/80⁺CD49b⁻) harvested from the BM and SP of NS and NS-Idd13 mice after treatment with control liposomes containing PBS, anti-CD122 Ab (CD122), or CLO liposomes. Data are expressed as mean ± SEM (n mice). CD122 and CLO treatment resulted in depletion of NK cells and macrophages, respectively, with concomitant enrichment of the opposite cell population in some cases.

*, P < 0.05 versus PBS (ANOVA).

**, P < 0.01 versus PBS (ANOVA).

***, P < 0.001 versus PBS (ANOVA).